GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Allergan, Inc. (AGN) [hlAlert]

Rating:
Buy AGN
up 684.96 %

Allergan, Inc. (AGN) rated Buy by Piper Jaffray

Posted on: Thursday,  Mar 12, 2009  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Buy Allergan, Inc. (NYSE: AGN) on 03/12/2009, when the stock price was $38.98. Since
then, Allergan, Inc. has gained 684.97% as of 11/24/2015's recent price of $305.98.
If you would have followed this Piper Jaffray's recommendation on AGN, you would have gained 684.96% of your investment in 2448 days.

Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics and medical devices. The Company is engaged in discovering, developing and commercializing specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries globally. In January 2007, the Company completed the acquisition of Groupe Corneal Laboratoires (Corneal). In October 2007, the Company completed the acquisition of Esprit Pharma Holding Company, Inc. (Esprit). In July 2008, the Company acquired the Aczone (dapsone) gel 5% from QLT USA, Inc. (QLT), a wholly owned subsidiary of QLT Inc. The Company operates in two business segments: specialty pharmaceuticals and medical devices.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/12/2009 8:25 AM Buy
None
38.98
as of 12/31/2009
1 Week up  13.92 %
1 Month up  22.75 %
3 Months up  25.72 %
1 YTD up  83.06 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy